Pancreatic Ductal Adenocarcinoma — Trials

Pancreatic Ductal Adenocarcinoma — Trials · CancerIndex

Clinical trials

Registered studies

414 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 208
Recruiting: 129
Ph III recruiting: 13
Growth YoY: +56.5%
Industry share: 50%
Top sponsor: Revolution Medicines, Inc.
Termination share: 46.8%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (56)

clinicaltrialsPublishedShowing 51–71 of 71 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05379985	Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS	recruiting	Phase 1 / Phase 2	754	Revolution Medicines, Inc.INDUSTRY	1	May 15, 2026	clinicaltrials
NCT04789486	Nano-SMART: Nanoparticles With MR Guided SBRT in Centrally Located Lung Tumors and Pancreatic Cancer	recruiting	Phase 1 / Phase 2	100	Dana-Farber Cancer InstituteOTHER	1	May 14, 2026	clinicaltrials